Viking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens
Go back to Viking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens| ING Van Kampen Equity Growth Fund S 2 Class (NASDAQ: VKTX) | Delayed: 26.38 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $26.38 | 52 Week High | $5.17 | |||
| Open | $26.38 | 52 Week Low | $0.94 | |||
| Day High | $26.38 | P/E | N/A | |||
| Day Low | $26.38 | EPS | $0.00 | |||
| Volume | 3,161 | |||||



